The Food and Drug Administration has broadened the use of evolocumab (Repatha), offering new hope for patients who struggle with statin side effects. Previously limited to those with heart disease and high LDL cholesterol, Repatha can now be prescribed for anyone with elevated lipids as of August 25, 2025.
Many patients report muscle pain, weakness, blood sugar spikes, and even cognitive issues tied to statins. Some cardiologists are already transitioning patients to Repatha, which has shown promising results in lowering cholesterol without the same side effects.
However, insurance approval remains a key factor in access. Advocates believe that high patient satisfaction may encourage broader coverage.
For more details, see the full report from People’s Pharmacy on OregonLive.